Similarly, in the Phase III ATTACH trial of another TNF-α antibody, infliximab, the percentage of death and heart failure-related hospitalization were not improved, although plasma levels of C-reactive protein (CRP) and IL-6 decreased after each injection. The gene discussed is TNF; the disease is heart failure.